drugset / Trial / NCT00849667
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
Timeline
- Start
- 2009-04-16
- Primary completion
- 2012-12-31
- Completion
- 2013-04-12
Outcome
Outcome not reported
Stopped: “Lack of efficacy”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Farletuzumab | Monoclonal antibody | 1.25 mg/kg | Intravenous |
| Comparator | Farletuzumab | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Comparator | Carboplatin | Small molecule | — | Intravenous |
| Comparator | Docetaxel | Small molecule | 75 mg/m2 | Intravenous |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |